An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.
A dose of MDMA from the MAPS Public Benefit Corp., which is now renamed as Lykos Therapeutics, a for-profit company whose studies the F.D.A. is analyzing.
Developed in 1912, MDMA was reclassified in 1985 as a Schedule I substance, a drug defined as having no accepted medical use and a high potential for abuse.
Login
